Brivaracetam

Brivaracetam (trade name Briviact), a chemical analog of levetiracetam, is a racetam derivative with anticonvulsant (antiepileptic) properties.On 14 January 2016, the European Commission,and on 12 May 2016, the U.S. Food and Drug Administration (FDA)  approved brivaracetam under the trade name Briviact. The Drug Enforcement Administration (DEA) issued an interim final rule^{[clarification needed]} placing brivaracetam into schedule V of the Controlled Substances Act (CSA) effective 9 March 2017. As of May 2016, brivaracetam is not approved in some other countries, such as Switzerland. It was approved in Australia in 2018.^{[citation needed]} In Canada it was approved on 9 March 2016 under the trade name Brivlera.